Sign in to view content

ARCHER II, a Phase 3 Randomized Clinical Trial of ANX007 in Patients With Dry AMD and GA: Study Design andRationale Informed by Outcomes From ARCHER

David A. Eichenbaum, MD, FASRS

Video
Published 2025

Related

Multiwavelength Photobiomodulation Significantly Reduces Risk for Vision Loss and Onset of Geographic Atrophy in Dry Age-Related Macular Degeneration
Eleonora Lad, MD, PhD
Updates from the Field
2024
Dry AMD Symposium 2
Annual Meeting Talks
2020
Inhibition of C1q Protects Photoreceptor Synapses in a Light Damage Model and Is a Potential Treatment for Geographic Atrophy
Patrick Dewey Williams, MD
Annual Meeting Talks
2022

Category: AMD-Non-Neovascular

See more